Yoichi Naito

Kashiwa, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 148 publications

Molecularly Guided Therapy Versus Continued Chemotherapy in Unfavorable Cancer of Unknown Primary: Updated Efficacy and Safety From the Randomized, Phase II CUPISCO Study.

Molecularly Guided Therapy Versus Continued Chemotherapy in Unfavorable Cancer of Unknown Primary: Updated Efficacy and Safety From the Randomized, Phase II CUPISCO Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 03, 2026

Plain language summary of the MiroCIP study: how often chemotherapy-induced peripheral neuropathy happens in the first year of oxaliplatin- or taxane-based chemotherapy.

Plain language summary of the MiroCIP study: how often chemotherapy-induced peripheral neuropathy happens in the first year of oxaliplatin- or taxane-based chemotherapy.

Journal: Future oncology (London, England)

Published: July 07, 2026

Personalized whole-genome-based ctDNA dynamics during neoadjuvant therapy across breast cancer subtypes: results from MONITOR-Breast.

Personalized whole-genome-based ctDNA dynamics during neoadjuvant therapy across breast cancer subtypes: results from MONITOR-Breast.

Journal: Future oncology (London, England)

Published: June 22, 2026

BRAF-Mutant Solid Tumor

BRAF-Mutant Solid Tumor

Journal: Gan to kagaku ryoho. Cancer & chemotherapy

Published: June 04, 2026

Correction: Differences in drug efficacy and prognosis between primary and metastatic sites for de novo stage IV breast cancer: an exploratory analysis of a phase III trial, JCOG1017.

Correction: Differences in drug efficacy and prognosis between primary and metastatic sites for de novo stage IV breast cancer: an exploratory analysis of a phase III trial, JCOG1017.

Journal: Breast cancer (Tokyo, Japan)

Published: May 29, 2026

Impact of medical oncologist certification on survival outcomes in metastatic colorectal cancer: evidence from the SCRUM-Japan MONSTAR-SCREEN Observational Study.

Impact of medical oncologist certification on survival outcomes in metastatic colorectal cancer: evidence from the SCRUM-Japan MONSTAR-SCREEN Observational Study.

Journal: International journal of clinical oncology

Published: April 20, 2026

Clinical benefit of paclitaxel/carboplatin plus bevacizumab with zoledronic acid in pulmonary epithelioid hemangioendothelioma complicated by hypertrophic pulmonary osteoarthropathy and cardiac tamponade: a case report.

Clinical benefit of paclitaxel/carboplatin plus bevacizumab with zoledronic acid in pulmonary epithelioid hemangioendothelioma complicated by hypertrophic pulmonary osteoarthropathy and cardiac tamponade: a case report.

Journal: Frontiers in oncology

Published: April 14, 2026

Primary tumour resection reduces the risk of major local morbidity in de novo stage IV breast cancer: secondary data analysis from the JCOG1017 randomized controlled trial.

Primary tumour resection reduces the risk of major local morbidity in de novo stage IV breast cancer: secondary data analysis from the JCOG1017 randomized controlled trial.

Journal: The British journal of surgery

Published: March 21, 2026

De-escalation of perioperative systemic therapy for early breast cancer.

De-escalation of perioperative systemic therapy for early breast cancer.

Journal: Japanese journal of clinical oncology

Published: March 21, 2026

De-escalation of breast surgery for early stage breast cancer.

De-escalation of breast surgery for early stage breast cancer.

Journal: Japanese journal of clinical oncology

Published: March 14, 2026

Genomic landscape of immune checkpoint inhibitor-induced aplastic anemia: a case report.

Genomic landscape of immune checkpoint inhibitor-induced aplastic anemia: a case report.

Journal: Frontiers in oncology

Published: February 01, 2026

Efficacy of perioperative pembrolizumab for triple-negative breast cancer with apocrine feature or metaplastic carcinoma.

Efficacy of perioperative pembrolizumab for triple-negative breast cancer with apocrine feature or metaplastic carcinoma.

Journal: The oncologist

Published: January 20, 2026

Showing 1-12 of 148

Last Updated: 09/26/2026